Compare Paychex, Inc. (PAYX) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Paychex, Inc. vs Summit Therapeutics Inc — how do they compare? Paychex, Inc. trades at $103.98 (market cap $37.19B), while Summit Therapeutics Inc trades at $17.59 (market cap $13.71B). The key difference: Paychex, Inc. is far larger — about 2.7× Summit Therapeutics Inc's market cap, and Paychex, Inc. pays a 4.56% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Paychex, Inc. for 56 Days and Summit Therapeutics Inc for 16 Days on average.
| PAYX | SMMT | |
|---|---|---|
Market Cap | $37.19B | $13.71B |
Volume | 3,344,316 | 6,173,057 |
Sector | Industrials | Health |
52-Week High | $128.59 | $26.38 |
52-Week Low | $85.57 | $12.43 |
Typical Hold Time | 56 Days | 16 Days |
Enterprise Value | $40.87B | $13.04B |
Dividend Yield | 4.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Paychex (PAYX) trades at $104.46, up 2.87% on the day, with a mixed technical outlook showing a bullish overall signal but bearish moving averages. The company continues to deliver strong fundamentals, beating earnings estimates for the last three quarters with a net income margin of 27.35% and robust ROE of 47.06%. Recent news highlights earnings beats but also concerns over stock performance and dividend sustainability despite a recent 5-star rating from Newsweek.
The stock presents a cautious opportunity with a consensus price target of $111 offering ~6% upside, but risks include a high P/E of 20.73, significant debt increase, and sensitivity to labor market trends. Investor sentiment is divided, with analyst consensus leaning Hold, reflecting balanced growth prospects against valuation and macroeconomic headwinds.
Summit Therapeutics (SMMT) trades at $17.17, down 4.35% on the day, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The company reported no revenue in 2025 and a net loss of $1.08 billion, with negative ROE and ROA, yet maintains a high P/B ratio of 21.76. Recent positive sentiment is driven by a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations for its lead drug ivonescimab, as reported by Reuters and Business Wire on September 28-29, 2026.
The outlook hinges on clinical success; upside exists if ivonescimab trials meet endpoints, supported by strong analyst consensus (65% buy rating) and a $29.33 price target. Key risks include cash burn from negative operating cash flow, drug development failures, and reliance on partnership outcomes, posing significant volatility for investors despite institutional interest.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
